Johns Hopkins HIV Guide
Telbivudine
INDICATIONS
FDA
FDA
- Treatment of chronic hepatitis B (HBeAg-negative or -positive) with ongoing viral replication and evidence of transferase elevation or histologically active disease.
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: July 8, 2018
Citation
Smith, Janessa M, and Paul A Pham. "Telbivudine." Johns Hopkins HIV Guide, 2018. Johns Hopkins Guides, www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine.
Smith JM, Pham PA. Telbivudine. Johns Hopkins HIV Guide. 2018. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine. Accessed December 6, 2023.
Smith, J. M., & Pham, P. A. (2018). Telbivudine. In Johns Hopkins HIV Guide https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine
Smith JM, Pham PA. Telbivudine [Internet]. In: Johns Hopkins HIV Guide. ; 2018. [cited 2023 December 06]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Telbivudine
ID - 545198
A1 - Smith,Janessa,Pharm.D., BCPS
AU - Pham,Paul,Pharm.D.
Y1 - 2018/07/08/
BT - Johns Hopkins HIV Guide
UR - https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_HIV_Guide/545198/all/Telbivudine
DB - Johns Hopkins Guides
DP - Unbound Medicine
ER -
